Placeholder

Naloxone

CAS No:
465-65-6 Category:
  • # LGM Pharma is a Naloxone CAS# 465-65-6 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Naloxone
  • CAS #: 465-65-6
  • Mode of Action:

    While the mechanism of action of naloxone is not fully understood, the preponderance of evidence suggests that naloxone antagonizes the opioid effects by competing for the same receptor sites, especially the opioid mu receptor. Recently, naloxone has been shown to bind all three opioid receptors (mu, kappa and gamma) but the strongest binding is to the mu receptor.

  • Pharmacodynamics:

    Naloxone is an opiate antagonist and prevents or reverses the effects of opioids including respiratory depression, sedation and hypotension. Also, it can reverse the psychotomimetic and dysphoric effects of agonist-antagonists such as pentazocine. Naloxone is an essentially pure narcotic antagonist, i.e., it does not possess the "agonistic" or morphine-like properties characteristic of other narcotic antagonists; naloxone does not produce respiratory depression, psychotomimetic effects or pupillary constriction. In the absence of narcotics or agonistic effects of other narcotic antagonists, it exhibits essentially no pharmacologic activity. When given intravenously, the onset of action is apparent within 2 minutes. The onset of action is slower if given subcutaneously or intramuscularly. The duration of action also differs between sites of injection and dose.

  • Metabolism:

    Naloxone is hepatically metabolized and primarily undergoes glucuronidation to form naloxone-3-glucuronide.

  • Toxicity:

    LD50, IV administration, mouse = 150 ± 5 mg/kg; LD50, IV administration, rat = 109 ± 4 mg/kg;

  • IUPAC: Morphinan-6-one, 17-allyl-4, 5alpha-epoxy-3, 14-dihydroxy- (8CI) Morphinan-6-one, 4, 5-alpha-epoxy-3, 14-dihydroxy-17-(2-propenyl)- Morphinan-6-one, 4, 5-epoxy-3, 14-dihydroxy-17-(2-propenyl)-, (5alpha)- Naloxone
  • ATC: V03AB15
  • DrugBank: DB01183
  • Formula: C19-H21-N-O4
  • Molecular Mass: 327.378
  • Synonyms: 1-N-Allyl-14-hydroxynordihydromorphinone, 1-N-Allyl-7,8-dihydro-14-hydroxynormorphinone, 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro(4,5-bcd)furanone, 17-Allyl-4,5-alpha-epoxy-3,14-dihydroxymorphinan-6-one, 17-Allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one, BRN 1089071, EINECS 207-365-7, EN 1530 base, HSDB 3279, l-N-Allyl-14-hydroxynordihydromorphinone, l-N-Allyl-7,8-dihydro-14-hydroxynormorphinone, l-Naloxone, Morphinan-6-one, 17-allyl-4,5alpha-epoxy-3,14-dihydroxy-, Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5alpha)-, Morphinan-6-one, 4,5alpha-epoxy-3,14-dihydroxy-17-(2-propenyl)-, N-Allyl-4,5alpha-epoxy-3,14-dihydroxy-6-morphinanon, N-Allyl-noroxymorphone, n-Allylnoroxymorphone, Nalossone, Nalossone [DCIT], Naloxona, Naloxona [INN-Spanish], Naloxone, Naloxone Nasal Spray, Naloxonum, Naloxonum [INN-Latin], Normorphinone, N-allyl-7,8-dihydro-14-hydroxy-, (-)-, NSC 70413, UNII-36B82AMQ7N
  • SMILES: c12[C@]34[C@@]5([C@H]([N@](CC=C)CC4)Cc2ccc(c1O[C@H]3C(=O)CC5)O)O
  • AHFS Code: 28:10.0
  • InChl: 1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1
  • General Reference:

     

    1. FDA label
    2. http://www.medscape.com/viewarticle/441915_3

     

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements